SEC Comment Letter 0000000000-24-008477 to Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc.
Date: July 26, 2024 · CIK: 0001659617 · Accession: 0000000000-24-008477
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-280951
Letter
July 25, 2024 Jonathan Foster Chief Financial Officer Moleculin Biotech, Inc. 5300 Memorial Drive, Suite 950 Houston, TX 7707 Re:Moleculin Biotech, Inc. Registration Statement on Form S-1 Filed July 22, 2024 File No. 333-280951 Dear Jonathan Foster: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jessica Dickerson at 202-551-8013 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Cavas S. Pavri, Esq.
Show Raw Text
July 25, 2024
Jonathan Foster
Chief Financial Officer
Moleculin Biotech, Inc.
5300 Memorial Drive, Suite 950
Houston, TX 7707
Re:Moleculin Biotech, Inc.
Registration Statement on Form S-1
Filed July 22, 2024
File No. 333-280951
Dear Jonathan Foster:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jessica Dickerson at 202-551-8013 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Cavas S. Pavri, Esq.